Head and Neck Cancer: Full Disease Coverage

  • ID: 4462202
  • Report
  • 221 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Head and neck cancer is the sixth most common cancer worldwide, and includes malignancies that can originate in the oral cavity, salivary glands, sinuses, and throat. Around 90% of cases have an epithelial origin, which present as squamous cell carcinomas. Environmental factors such as tobacco smoking and alcohol consumption greatly increase the risk of developing head and neck cancers. If diagnosed at an early stage, treatment for these cancers can be curative; however, the majority of patients are diagnosed when the disease is advanced, resulting in the need for more than one treatment modality.

Market Snapshot
  • The head and neck cancer market is projected to reach $2.8bn in value by 2026, with growth driven by immunotherapies.
  • Erbitux continues to be the primary targeted therapy prescribed for the treatment of advanced head and neck cancer.
  • The incident population of this common cancer is predicted to increase over the forecast period of 2016-36.
  • Erbitux’s position as the leading targeted therapy for SCCHN is being challenged as immunotherapies enter the market.
  • Immunotherapy developers will look to minimize direct competition in SCCHN by targeting new patient settings.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: HEAD AND NECK CANCER
Executive Summary
Market Overview and Trends
Market Definition and Methodology
durvalumab
Erbitux (cetuximab)
Gilotrif (afatinib)
Javlor (vinflunine ditartrate)
Keytruda (pembrolizumab)
Multikine
Opdivo (nivolumab)
Reolysin
TS-1 (gimeracil/oteracil potassium/tegafur)
Primary Research Methodology

TREATMENT: HEAD AND NECK CANCER
Executive Summary
Primary Research Methodology
Disease Definition and Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends

EPIDEMIOLOGY: HEAD AND NECK CANCER
Executive Summary
Disease Background
Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: HEAD AND NECK CANCER
Executive Summary
Product Overview
Product profile: Erbitux

PIPELINE: HEAD AND NECK CANCER
Executive Summary
Clinical Pipeline Overview
Recently Discontinued Drugs
Comparator Therapy
Product profile (late stage): Gilotrif
Product profile (late stage): Javlor
Product profile (late stage): Keytruda
Product profile (late stage): Multikine
Product profile (late stage): Opdivo
Product profile (late stage): Reolysin
Product profile (late stage): durvalumab

List of Figures
Figure 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 2: SCCHN drug sales in the US, Japan, and five major EU markets, by status ($m), 2015-24
Figure 3: SCCHN drug sales in the US, by status ($m), 2015-24
Figure 4: SCCHN drug sales in Japan, by status ($m), 2015-24
Figure 5: SCCHN drug sales in the five major EU markets, by status ($m), 2015-24
Figure 6: Methodology flow
Figure 7: Price sources and calculations, by country
Figure 8: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 9: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 10: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 11: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
Figure 12: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 13: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 14: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 15: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Figure 16: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
Figure 17: HPV screening rates and outcomes among SCCHN patients, by country
Figure 18: Proportion of prevalent SCCHN patients in each stage of disease, by country
Figure 19: Proportion of Stage I and Stage II SCCHN patients receiving each treatment type, by country
Figure 20: Percentage of Stage III SCCHN patients receiving each treatment type, by country
Figure 21: Percentage of Stage III SCCHN patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
Figure 22: Top three regimens used in the adjuvant treatment of Stage III SCCHN patients, by country
Figure 23: Percentage of Stage IV SCCHN patients receiving each treatment type, by country
Figure 24: Top three regimens used in the first-line treatment of Stage IV SCCHN patients who receive pharmacological therapy without surgery, by country
Figure 25: Percentage of Stage IV SCCHN patients who progress from first- to second-line therapy or from second- to thirdline therapy, by country
Figure 26: Top three regimens used for the second-line treatment of Stage IV SCCHN patients, by country
Figure 27: Percentage of local relapse SCCHN patients receiving each treatment type, by country
Figure 28: Top three regimens used in the first-line treatment of local relapse SCCHN patients receiving pharmacological therapy without surgery, by country
Figure 29: Top three regimens used in the second-line treatment of local relapse SCCHN patients, by country
Figure 30: Percentage of distant relapse SCCHN patients receiving each treatment type, by country
Figure 31: Top three regimens used in the first-line treatment of distant relapse SCCHN patients who receive pharmacological therapy without surgery, by country
Figure 32: Top three regimens used in the second-line treatment of distant relapse SCCHN patients, by country
Figure 33: Trends in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
Figure 34: Absolute change in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
Figure 35: Age-specific trends in incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
Figure 36: Erbitux for head and neck cancer - SWOT analysis
Figure 37: Drug assessment summary of Erbitux for head and neck cancer
Figure 38: Drug assessment summary of Erbitux for head and neck cancer
Figure 39: Gilotrif for head and neck cancer - SWOT analysis
Figure 40: Drug assessment summary of Gilotrif for head and neck cancer
Figure 41: Drug assessment summary of Gilotrif for head and neck cancer
Figure 42: Javlor for head and neck cancer - SWOT analysis
Figure 43: Drug assessment summary of Javlor for head and neck cancer
Figure 44: Drug assessment summary of Javlor for head and neck cancer
Figure 45: Keytruda for head and neck cancer - SWOT analysis
Figure 46: Drug assessment summary of Keytruda for head and neck cancer
Figure 47: Drug assessment summary of Keytruda for head and neck cancer
Figure 48: Multikine for head and neck cancer - SWOT analysis
Figure 49: Drug assessment summary of Multikine for head and neck cancer
Figure 50: Drug assessment summary of Multikine for head and neck cancer
Figure 51: Opdivo for head and neck cancer - SWOT analysis
Figure 52: Drug assessment summary of Opdivo for head and neck cancer
Figure 53: Drug assessment summary of Opdivo for head and neck cancer
Figure 54: Reolysin for head and neck cancer - SWOT analysis
Figure 55: Drug assessment summary of Reolysin for head and neck cancer
Figure 56: Drug assessment summary of Reolysin for head and neck cancer
Figure 57: Durvalumab for head and neck cancer - SWOT analysis
Figure 58: Drug assessment summary of durvalumab for head and neck cancer
Figure 59: Drug assessment summary of durvalumab for head and neck cancer

List of Tables
Table 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 2: SCCHN drug sales in the US, Japan, and five major EU markets, by brand and status ($m), 2015-24
Table 3: SCCHN drug sales in the US, by brand and status ($m), 2015-24
Table 4: SCCHN drug sales in Japan, by brand and status ($m), 2015-24
Table 5: SCCHN drug sales in the five major EU markets, by brand and status ($m), 2015-24
Table 6: Summary of drug classes, molecules, and brands included in the SCCHN patient-based forecast
Table 7: Exchange rates used for calculating prices
Table 8: Patent expiry dates for key marketed brands in SCCHN, by region
Table 9: Estimated approval dates of key late-stage pipeline products in SCCHN, by region
Table 10: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 11: Durvalumab patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 12: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 13: Erbitux patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 14: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 15: Gilotrif patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 16: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
Table 17: Javlor patient numbers for SCCHN in the five major EU markets, by country, 2015-24
Table 18: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 19: Keytruda patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 20: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 21: Multikine patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 22: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 23: Opdivo patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 24: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 25: Reolysin patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
Table 26: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
Table 27: TS-1 patient numbers for SCCHN in Japan, 2015-24
Table 28: Physicians surveyed for the squamous cell carcinoma of the head and neck primary research study, 2015
Table 29: Physicians surveyed for the head and neck cancer primary research study, 2017
Table 30: Oral cavity and pharynx cancer five-year survival rates, by stage at diagnosis, 2007-13
Table 31: TNM stage classification
Table 32: Leading treatments for SCCHN
Table 33: Head and neck cancer site codes according to ICD-10
Table 34: Cancer registry databases used as a source of HNC incidence data, by country
Table 35: Forecasting methodology for HNC incidence, by country, age group, and gender
Table 36: Sources of survival data used to estimate HNC prevalence, by country/region
Table 37: Diagnosed incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
Table 38: Age-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
Table 39: Gender-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
Table 40: Validation of forecast estimates against benchmark estimates
Table 41: Key marketed drugs for head and neck cancer
Table 42: Erbitux drug profile
Table 43: Erbitux pivotal trial data in head and neck cancer
Table 44: Late-stage pipeline products in development for head and neck cancer
Table 45: Late-stage compounds that were recently discontinued for head and neck cancer
Table 46: Erbitux drug profile
Table 47: Gilotrif drug profile
Table 48: Gilotrif Phase III trials in head and neck cancer
Table 49: Gilotrif Phase III data in head and neck cancer
Table 50: Javlor drug profile
Table 51: Javlor Phase III trials in head and neck cancer
Table 52: Keytruda drug profile
Table 53: Keytruda Phase III trials in head and neck cancer
Table 54: Keytruda topline early-phase data in head and neck cancer
Table 55: Overview of Phase Ib trial data for Keytruda in PD-L1-positive head and neck cancer patients
Table 56: Multikine drug profile
Table 57: Multikine Phase III trials in head and neck cancer
Table 58: Overview of Phase II trial data for Multikine in head and neck cancer
Table 59: Opdivo drug profile
Table 60: Ongoing Opdivo Phase III trials in head and neck cancer
Table 61: Opdivo Phase III data in head and neck cancer
Table 62: Reolysin drug profile
Table 63: Reolysin Phase III data in head and neck cancer
Table 64: Durvalumab drug profile
Table 65: Durvalumab Phase III and pivotal Phase II trials in head and neck cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll